Production (Stage)
CG Oncology, Inc.
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.09% | 278.41% | 128.00% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.09% | 278.41% | 128.00% | -- | -- |
| Cost of Revenue | 76.86% | 91.59% | 109.66% | -- | -- |
| Gross Profit | -77.73% | -90.23% | -109.44% | -- | -- |
| SG&A Expenses | 214.42% | 241.57% | 194.01% | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 105.26% | 119.66% | 126.47% | -- | -- |
| Operating Income | -106.21% | -118.71% | -126.42% | -- | -- |
| Income Before Tax | -91.07% | -87.41% | -87.55% | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -91.07% | -87.41% | -87.55% | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -91.07% | -87.41% | -87.55% | -- | -- |
| EBIT | -106.21% | -118.71% | -126.42% | -- | -- |
| EBITDA | -106.18% | -118.72% | -126.42% | -- | -- |
| EPS Basic | 87.72% | 90.66% | 61.91% | -- | -- |
| Normalized Basic EPS | 83.59% | 87.23% | 58.59% | -- | -- |
| EPS Diluted | 87.72% | 90.66% | 61.91% | -- | -- |
| Normalized Diluted EPS | 83.59% | 87.23% | 58.59% | -- | -- |
| Average Basic Shares Outstanding | 364.80% | 1,385.51% | 1,103.38% | -- | -- |
| Average Diluted Shares Outstanding | 364.80% | 1,385.51% | 1,103.38% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |